Auscann Group Holdings Ltd (ASX: AC8) and Cann Group Ltd (ASX: CAN) weren?t the only pot stocks to enjoy rapid gains on Thursday.
While Cann Group?s share price was up by an incredible 35 per cent and Auscann?s jumped by more than 50 per cent, another pot stock, BOD Australia Ltd (ASX: BDA), also enjoyed a staggering ascent with its shares price climbing by almost 40 per cent.
Numerous pot stocks across the board, including MGC Pharmaceuticals Ltd (ASX: MXC), Creso Pharma Ltd (ASX: CPH) and the Hydroponics Company Ltd (ASX: THC), all enjoyed big gains following an announcement of a loosening…
To keep reading, enter your email address or login below.
While Cann Group’s share price was up by an incredible 35 per cent and Auscann’s jumped by more than 50 per cent, another pot stock, BOD Australia Ltd (ASX: BDA), also enjoyed a staggering ascent with its shares price climbing by almost 40 per cent.
Numerous pot stocks across the board, including MGC Pharmaceuticals Ltd (ASX: MXC), Creso Pharma Ltd (ASX: CPH) and the Hydroponics Company Ltd (ASX: THC), all enjoyed big gains following an announcement of a loosening of restrictions concerning the exportation of cannabis products.
But BOD Australia went one step further to other pot stocks, announcing it had struck an agreement with Singapore-listed iX Biopharma Ltd (SGX: 42C) which could allow BOD Australia to capitalise on the changes to regulations.
BOD Australia, a developer and distributor of natural cosmetics and medicines, announced it has entered into an agreement to supply iX Biopharma with a range of medicinal cannabis extracts including oils and raw materials.
BOD Australia stated iX Biopharma will utilise BOD’s products to create a “unique natural medicine product”.
iX Biopharma intends to produce a wafer, similar to a thin biscuit, which releases “active compounds for rapid absorption” when placed under the consumer’s tongue.
Trials of the new drug are set to commence this year.
BOD Australia CEO Jo Patterson said the upcoming “Phase I Clinical trials are incredibly important for the company as they will lead the development of specific therapeutic indications for Bod’s medicinal cannabis product suite”.
“We are currently investigating ways to advance our Phase I Clinical trial design to reduce time to market and cost savings, and look forward to updating shareholders as this progresses,” Ms Patterson said.
In financial year 2017 BOD Australia reported a loss of $3.2 million on revenues of $350,000.
For many, blue chip stocks mean stability, profitability and regular dividends, often fully franked..
But knowing which blue chips to buy, and when, can be fraught with danger.
The Motley Fool's in-house analyst team has poured over thousands of hours worth of proprietary research to bring you the names of "The Motley Fool's Top 3 Blue Chip Stocks for 2018."
Each one pays a fully franked dividend. Each one has not only grown its profits, but has also grown its dividend. One increased it by a whopping 33%, while another trades on a grossed up (fully franked) dividend yield of almost 7%.
The names of these Top 3 ASX Blue Chips are included in this specially prepared free report. But you will have to hurry. Depending on demand - and how quickly the share prices of these companies moves - we may be forced to remove this report.
Click here to claim your free report.
Motley Fool contributor Steve Holland has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.